BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005;103:148-156. [PMID: 15558794 DOI: 10.1002/cncr.20724] [Cited by in Crossref: 171] [Cited by in F6Publishing: 137] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Menon N, Mandelkern M. Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. Dig Dis Sci 2022. [PMID: 35908126 DOI: 10.1007/s10620-022-07616-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Kitasaki N, Okada M. Blood biomarkers as predictors of pathological lymph node metastasis in clinical stage T1N0 esophageal squamous cell carcinoma. Dis Esophagus 2022:doac042. [PMID: 35780322 DOI: 10.1093/dote/doac042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hsu SW, Chang JS, Chang WL, Lin FC, Chiu NT. Measuring distance from the incisors to the esophageal cancer by FDG PET/CT: endoscopy as the reference. BMC Gastroenterol 2022;22:126. [PMID: 35300618 DOI: 10.1186/s12876-022-02206-z] [Reference Citation Analysis]
4 Be KH, Khor R, Lim Joon D, Starvaggi B, Chao M, Ng SP, Ng M, Zorron Cheng Tao Pu L, Efthymiou M, Vaughan R, Chandran S. Long-term clinical outcomes of lipiodol marking using standard gastroscopy for image-guided radiotherapy of upper gastrointestinal cancers. World J Gastroenterol 2021; 27(42): 7387-7401 [PMID: 34876797 DOI: 10.3748/wjg.v27.i42.7387] [Reference Citation Analysis]
5 Shashi KK, Madan R, Hammer MM, van Hedent S, Byrne SC, Schmidlin EJ, Mamon H, Hatabu H, Enzinger PC, Gerbaudo VH. Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferences. Eur J Radiol Open 2020;7:100291. [PMID: 33304940 DOI: 10.1016/j.ejro.2020.100291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Xu QL, Li H, Zhu YJ, Xu G. The treatments and postoperative complications of esophageal cancer: a review. J Cardiothorac Surg. 2020;15:163. [PMID: 32631428 DOI: 10.1186/s13019-020-01202-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wakita A, Motoyama S, Sato Y, Kawakita Y, Nagaki Y, Terata K, Imai K, Minamiya Y. Evaluation of metastatic lymph nodes in cN0 thoracic esophageal cancer patients with inconsistent pathological lymph node diagnosis. World J Surg Oncol 2020;18:111. [PMID: 32471425 DOI: 10.1186/s12957-020-01880-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
8 Miyawaki Y, Sato H, Fujiwara N, Oya S, Sugita H, Hirano Y, Yamane T, Sakuramoto S, Okamoto K, Yamaguchi S, Koyama I. Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study. Int J Clin Oncol 2020;25:561-9. [PMID: 31867680 DOI: 10.1007/s10147-019-01606-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Umetsu A, Shimizu T, Iwamoto N, Hashiguchi K, Eguchi M, Okamoto M, Endo Y, Tsuji S, Takatani A, Igawa T, Sumiyoshi R, Koga T, Kawashiri SY, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kawakami A. Paraneoplastic Syndrome Presenting with Polymyalgia Rheumatica-like Accumulations on 18F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography. Intern Med 2019;58:861-4. [PMID: 30449806 DOI: 10.2169/internalmedicine.1847-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Zhu Y, Fu L, Jing W, Guo D, Chen Y, Kong L, Yu J. The value of magnetic resonance imaging in esophageal carcinoma: Tool or toy? Asia‐Pac J Clin Oncol 2019;15:101-7. [DOI: 10.1111/ajco.13112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K, Tsurusaki M, Doi H, Ueno Y, Sofue K, Tamaki Y, Yamakado K. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. Nagoya J Med Sci 2017;79:527-43. [PMID: 29238109 DOI: 10.18999/nagjms.79.4.527] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
12 Nakajima M, Muroi H, Yokoyama H, Kikuchi M, Yamaguchi S, Sasaki K, Kato H. 18 F-Fluorodeoxyglucose positron emission tomography can be used to determine the indication for endoscopic resection of superficial esophageal cancer. Cancer Med. 2018;7:3604-3610. [PMID: 29953743 DOI: 10.1002/cam4.1628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
13 Udagawa H, Ueno M. Comparison of two major staging systems of esophageal cancer-toward more practical common scale for tumor staging. Ann Transl Med 2018;6:76. [PMID: 29666799 DOI: 10.21037/atm.2018.01.27] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
14 Goense L, Heethuis SE, van Rossum PS, Voncken FE, Lagendijk JJ, Lam MG, Terhaard CH, van Hillegersberg R, Ruurda JP, Mook S, van Lier AL, Lin SH, Meijer GJ. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer. Nuclear Medicine Communications 2018;39:60-7. [DOI: 10.1097/mnm.0000000000000771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
15 Almuhaideb A, Papathanasiou N, Bomanji J. 18 F-FDG PET/CT Imaging in Oncology. Ann Saudi Med 2011;31:3-13. [DOI: 10.5144/0256-4947.2011.3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
16 Amakusa S, Matsuoka K, Kawano M, Hasegawa K, Ouchida M, Date A, Yoshida T, Sasaki M. Influence of region-of-interest determination on measurement of signal-to-noise ratio in liver on PET images. Ann Nucl Med 2018;32:1-6. [PMID: 29058224 DOI: 10.1007/s12149-017-1215-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Yokota T, Yasuda T, Kato H, Nozaki I, Sato H, Miyata Y, Kuroki Y, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Kitagawa Y. Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. Int J Clin Oncol 2018;23:73-80. [PMID: 28744724 DOI: 10.1007/s10147-017-1168-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Liu J, Wang Z, Shao H, Qu D, Liu J, Yao L. Improving CT detection sensitivity for nodal metastases in oesophageal cancer with combination of smaller size and lymph node axial ratio. Eur Radiol 2018;28:188-95. [PMID: 28677059 DOI: 10.1007/s00330-017-4935-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
19 Encaoua J, Abgral R, Leleu C, El Kabbaj O, Caradec P, Bourhis D, Pradier O, Schick U. Intérêt de la tomographie par émission de positons au ( 18 F)-fluorodésoxyglucose pour la planification de la radiothérapie des cancers de l’œsophage localement évolués ou inopérables. Cancer/Radiothérapie 2017;21:267-75. [DOI: 10.1016/j.canrad.2016.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Yamatsuji T, Ishida N, Takaoka M, Hayashi J, Yoshida K, Shigemitsu K, Urakami A, Haisa M, Naomoto Y. False-Positive Cases of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomographic Scans in Metastasis of Esophageal Cancer. Clin Med Insights Case Rep 2017;10:1179547617703402. [PMID: 28469502 DOI: 10.1177/1179547617703402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Sekiguchi M, Terauchi T, Kakugawa Y, Shimada N, Saito Y, Matsuda T. Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening. World J Gastroenterol 2017; 23(15): 2743-2749 [PMID: 28487611 DOI: 10.3748/wjg.v23.i15.2743] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
22 Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy. BMC Med Imaging 2017;17:1. [PMID: 28056868 DOI: 10.1186/s12880-016-0171-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
23 Garcia B, Goodman KA, Cambridge L, Dunphy M, Wu AJ. Distribution of FDG-avid nodes in esophageal cancer: implications for radiotherapy target delineation. Radiat Oncol 2016;11:156. [PMID: 27887643 DOI: 10.1186/s13014-016-0731-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
24 Wareham NE, Lundgren JD, Da Cunha-Bang C, Gustafsson F, Iversen M, Johannesen HH, Kjær A, Rasmussen A, Sengeløv H, Sørensen SS, Fischer BM. The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. Eur J Nucl Med Mol Imaging 2017;44:421-31. [PMID: 27838763 DOI: 10.1007/s00259-016-3564-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
25 Lu J, Sun XD, Yang X, Tang XY, Qin Q, Zhu HC, Cheng HY, Sun XC. Impact of PET/CT on radiation treatment in patients with esophageal cancer: A systematic review. Crit Rev Oncol Hematol 2016;107:128-37. [PMID: 27823640 DOI: 10.1016/j.critrevonc.2016.08.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
26 Ma C, Li D, Yin Y, Cao J. Comparison of characteristics of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET during staging of esophageal squamous cell carcinoma. Nucl Med Commun. 2015;36:1181-1186. [PMID: 26367213 DOI: 10.1097/mnm.0000000000000378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Goense L, van Rossum PS, Kandioler D, Ruurda JP, Goh KL, Luyer MD, Krasna MJ, van Hillegersberg R. Stage-directed individualized therapy in esophageal cancer. Ann N Y Acad Sci 2016;1381:50-65. [PMID: 27384385 DOI: 10.1111/nyas.13113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
28 Simianu VV, Varghese TK Jr, Flanagan MR, Flum DR, Shankaran V, Oelschlager BK, Mulligan MS, Wood DE, Pellegrini CA, Farjah F. Positron emission tomography for initial staging of esophageal cancer among medicare beneficiaries. J Gastrointest Oncol 2016;7:395-402. [PMID: 27284472 DOI: 10.21037/jgo.2015.10.03] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Foley KG, Powell A, Lewis WG, Roberts SA. The 100 most cited articles investigating the radiological staging of oesophageal and junctional cancer: a bibliometric analysis. Insights Imaging 2016;7:619-28. [PMID: 27278388 DOI: 10.1007/s13244-016-0505-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
30 Liu S, Zhu H, Li W, Zhang B, Ma L, Guo Z, Huang Y, Song P, Yu J, Guo H. Potential impact of (18)FDG-PET/CT on surgical approach for operable squamous cell cancer of middle-to-lower esophagus. Onco Targets Ther 2016;9:855-62. [PMID: 26955283 DOI: 10.2147/OTT.S97896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Kim SJ, Koo PJ, Chang S. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients. Cancer Chemother Pharmacol 2016;77:723-31. [PMID: 26891957 DOI: 10.1007/s00280-016-2988-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
32 Griffin Y. Esophageal Cancer: Role of Imaging in Primary Staging and Response Assessment Post Neoadjuvant Therapy. Semin Ultrasound CT MR 2016;37:339-51. [PMID: 27342898 DOI: 10.1053/j.sult.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
33 Kim SJ, Pak K, Chang S. Determination of regional lymph node status using (18)F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumoral heterogeneity. Br J Radiol 2016;89:20150673. [PMID: 26607643 DOI: 10.1259/bjr.20150673] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
34 Peyraga G, Capitain O, Rousseau D, Rio E, Septans AL, Baton O, Marquis A, Trémolières P, Gustin P, Ménager É, Branger F, Bressolette M, Deutsch É, Paumier A. [Are extensive fields useful for radiotherapy of esophageal cancer?]. Cancer Radiother 2015;19:313-21. [PMID: 26232314 DOI: 10.1016/j.canrad.2015.03.011] [Reference Citation Analysis]
35 Hocazade C, Özdemir N, Yazici O, Bozkaya Y, Yazılıtaş D, Toptaş Ş, Zengin N, Deren T. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer. Ann Nucl Med 2015;29:621-6. [DOI: 10.1007/s12149-015-0985-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
36 Agrawal A, Rangarajan V. Appropriateness criteria of FDG PET/CT in oncology. Indian J Radiol Imaging 2015;25:88-101. [PMID: 25969632 DOI: 10.4103/0971-3026.155823] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
37 Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, Alberini JL, Lièvre A; Fédération Francophone de Cancérologie Digestive (FFCD). Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 2015;47:443-54. [PMID: 25766918 DOI: 10.1016/j.dld.2015.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
38 Khanna LG, Gress FG. Preoperative evaluation of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:179-191. [PMID: 25743465 DOI: 10.1016/j.bpg.2014.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
39 van Rossum P, van Lier A, Lips I, Meijer G, Reerink O, van Vulpen M, Lam M, van Hillegersberg R, Ruurda J. Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clinical Radiology 2015;70:81-95. [DOI: 10.1016/j.crad.2014.07.017] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
40 Yi HJ, Hong KS, Moon N, Chung SS, Lee RA, Kim KH. Reliability of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in the nodal staging of colorectal cancer patients. Ann Coloproctol. 2014;30:259-265. [PMID: 25580412 DOI: 10.3393/ac.2014.30.6.259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
41 Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA. PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer 2015;14:35-40. [PMID: 25481195 DOI: 10.1016/j.clcc.2014.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
42 Erhunmwunsee L, Englum BR, Onaitis MW, D'Amico TA, Berry MF. Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions. Ann Surg Oncol. 2015;22:1020-1025. [PMID: 25234017 DOI: 10.1245/s10434-014-4079-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
43 Wani S, Das A, Rastogi A, Drahos J, Ricker W, Parsons R, Bansal A, Yen R, Hosford L, Jankowski M. Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: results from a population-based study. Cancer. 2015;121:194-201. [PMID: 25236485 DOI: 10.1002/cncr.29043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
44 Dai T, Popa E, Shah MA. The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies. Curr Treat Options in Oncol 2014;15:351-64. [DOI: 10.1007/s11864-014-0301-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
45 Karashima R, Watanabe M, Imamura Y, Ida S, Baba Y, Iwagami S, Miyamoto Y, Sakamoto Y, Yoshida N, Baba H. Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer. Surg Today. 2015;45:471-477. [PMID: 24969050 DOI: 10.1007/s00595-014-0965-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
46 Kim KS, Choi SR, Park IC, Koo TH, Kim JM. [Prognostic value of preoperative positron emission tomography-computed tomography in surgically resected gastric cancer]. Korean J Gastroenterol 2014;63:348-53. [PMID: 24953611 DOI: 10.4166/kjg.2014.63.6.348] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Ida S, Watanabe M, Yamao T, Ishimoto T, Nagai Y, Iwatsuki M, Baba Y, Iwagami S, Sakamoto Y, Miyamoto Y, Baba H. False-positive 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) findings of bone metastasis from esophagogastric cancer: report of two cases. Surg Today 2014;44:2191-4. [DOI: 10.1007/s00595-014-0947-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
48 Ichikawa T, Hashimoto J, Yabe M, Kikuchi T, Imai Y. Detection of Early Esophageal Cancer and Cervical Lymph Node Metastases by 18F-FDG PET/CT in a Patient With Fanconi Anemia. Clinical Nuclear Medicine 2014;39:459-61. [DOI: 10.1097/rlu.0000000000000417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Seol KH, Lee JE. PET/CT planning during chemoradiotherapy for esophageal cancer. Radiat Oncol J 2014;32:31-42. [PMID: 24724049 DOI: 10.3857/roj.2014.32.1.31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
50 Shin S, Kim HK, Choi YS, Kim K, Shim YM. Clinical stage T1–T2N0M0 oesophageal cancer: accuracy of clinical staging and predictive factors for lymph node metastasis†. European Journal of Cardio-Thoracic Surgery 2014;46:274-9. [DOI: 10.1093/ejcts/ezt607] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
51 Jo HJ, Kim SJ, Kim IJ, Kim S. Predictive value of volumetric parameters measured by F-18 FDG PET/CT for lymph node status in patients with surgically resected rectal cancer. Ann Nucl Med 2014;28:196-202. [PMID: 24532377 DOI: 10.1007/s12149-014-0809-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
52 Tomizawa M, Shinozaki F, Ozaki A, Baba A, Fukamizu Y, Matsunaga F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T. Diffusion-weighted imaging and diffusion-weighted whole-body imaging with background body signal suppression for characterizing esophageal cancer: a case report. Int Med Case Rep J 2013;6:95-8. [PMID: 24324347 DOI: 10.2147/IMCRJ.S41823] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Ann Surg Oncol 2014;21:575-82. [PMID: 24201746 DOI: 10.1245/s10434-013-3343-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
54 Banks KP, Song WS. Role of positron emission tomography-computed tomography in gastrointestinal malignancies. Radiol Clin North Am 2013;51:799-831. [PMID: 24010907 DOI: 10.1016/j.rcl.2013.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
55 Wu AJ, Goodman KA. Positron emission tomography imaging for gastroesophageal junction tumors. Semin Radiat Oncol. 2013;23:10-15. [PMID: 23207042 DOI: 10.1016/j.semradonc.2012.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
56 Qiu GQ, Du XH, Yu JP, Zheng YD, Luo HJ, Xu YP, Chen JX, Sun XJ, Ji YL, Tao YL. The value of endoscopic ultrasonography in defining longitudinal gross target volumes for esophageal squamous carcinoma. Surg Laparosc Endosc Percutan Tech 2012;22:424-8. [PMID: 23047386 DOI: 10.1097/SLE.0b013e31825d393d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
57 Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg 2013;61:330-5. [PMID: 23568356 DOI: 10.1007/s11748-013-0246-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 103] [Article Influence: 8.7] [Reference Citation Analysis]
58 Manabe O, Hattori N, Hirata K, Itoh K, Hosokawa M, Takahashi H, Oyama-Manabe N, Tamaki N. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer. J Nucl Med 2013;54:670-6. [PMID: 23516310 DOI: 10.2967/jnumed.112.110304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
59 Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230-244. [PMID: 23296250 DOI: 10.1038/nrgastro.2012.236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
60 Ulla M, Gentile EM, Cavadas D, Yeyati EL, Frank L, Argerich JI, Garcia Mónaco R. Esophageal cancer characterization with pneumo-64-MDCT. Abdom Imaging. 2012;37:501-511. [PMID: 21842399 DOI: 10.1007/s00261-011-9784-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
61 Yun H, Shim K. Role of 18 F 2-fluoro-2-deoxyglucose Positron Emission Tomography in Upper Gastrointestinal Malignancies. Korean J Gastroenterol 2013;61:303. [DOI: 10.4166/kjg.2013.61.6.303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Kita Y, Okumura H, Uchikado Y, Sasaki K, Omoto I, Matsumoto M, Setoyama T, Tanoue K, Mori S, Owaki T, Ishigami S, Ueno S, Kajiya Y, Natsugoe S. Clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial esophageal squamous cell carcinoma. Ann Surg Oncol. 2013;20:1646-1652. [PMID: 23238695 DOI: 10.1245/s10434-012-2796-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
63 Sun M, Li B, Fu Z, Wei Y, Zhang J, Sun H, Li H, Feng R. Relationship between (18)F-fluorodeoxyglucose uptake in primary lesions and clinicopathological characteristics of esophageal squamous cell carcinoma patients. Exp Ther Med 2013;5:170-4. [PMID: 23251261 DOI: 10.3892/etm.2012.772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
64 Cincibuch J, Mysliveček M, Melichar B, Neoral Č, Metelková I, Zezulová M, Procházková-Študentová H, Flodr P, Zlevorová M, Aujeský R, Cwiertka K. Metastases of esophageal carcinoma to skeletal muscle: Single center experience. World J Gastroenterol 2012; 18(35): 4962-4966 [PMID: 23002370 DOI: 10.3748/wjg.v18.i35.4962] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
65 Li SH, Huang YC, Huang WT, Lin WC, Liu CT, Tien WY, Lu HI. Is there a role of whole-body bone scan in patients with esophageal squamous cell carcinoma. BMC Cancer 2012;12:328. [PMID: 22853826 DOI: 10.1186/1471-2407-12-328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
66 Yabuki K, Kubota A, Horiuchi C, Taguchi T, Nishimura G, Inamori M. Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma. Eur Arch Otorhinolaryngol 2013;270:727-33. [DOI: 10.1007/s00405-012-2081-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
67 Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53:864-871. [PMID: 22582047 DOI: 10.2967/jnumed.111.101568] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
68 Yu L, Tian M, Gao X, Wang D, Qin Y, Geng J. The method and efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing the lymphatic metastasis of colorectal carcinoma. Acad Radiol 2012;19:427-33. [PMID: 22265721 DOI: 10.1016/j.acra.2011.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
69 Kumar P, Damle NA, Bal C. Role of F18-FDG PET/CT in the Staging and Restaging of Esophageal Cancer: A Comparison with CECT. Indian J Surg Oncol 2011;2:343-50. [PMID: 23204793 DOI: 10.1007/s13193-012-0128-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
70 Hsieh TC, Wu YC, Sun SS, Chiang IP, Yang CF, Yen KY, Kao CH. Synchronous squamous cell carcinomas of the esophagus and renal pelvis. Clin Nucl Med 2011;36:e171-4. [PMID: 21975416 DOI: 10.1097/RLU.0b013e3182291b28] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
71 Marzola MC, De Manzoni G, Grassetto G, Cordiano C, Al-nahhas A, Alavi A, Rubello D. Extended staging of oesophageal cancer using FDG-PET – A critical appraisal. European Journal of Radiology 2012;81:21-30. [DOI: 10.1016/j.ejrad.2010.10.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
72 Tanabe S, Naomoto Y, Shirakawa Y, Fujiwara Y, Sakurama K, Noma K, Takaoka M, Yamatsuji T, Hiraki T, Okumura Y. F-18 FDG PET/CT contributes to more accurate detection of lymph nodal metastasis from actively proliferating esophageal squamous cell carcinoma. Clin Nucl Med. 2011;36:854-859. [PMID: 21892033 DOI: 10.1097/RLU.0b013e318217adc9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
73 Smyth EC, Shah MA. Role of (18F) 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol 2011; 17(46): 5059-5074 [PMID: 22171140 DOI: 10.3748/wjg.v17.i46.5059] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
74 Vyas S, Markar SR, Iordanidou L, Read S, Stoker D, Hashemi M, Mitchell I, Winslet M, Bomanji J. The role of integrated F-18-FDG-PET scanning in the detection of M1 disease in oesophageal adenocarcinoma and impact on clinical management. J Gastrointest Surg 2011;15:2127-35. [PMID: 21964582 DOI: 10.1007/s11605-011-1686-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Cohen DJ, Ajani J. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother 2011;12:225-39. [PMID: 21226634 DOI: 10.1517/14656566.2010.517748] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
76 Nakajo M, Nakajo M, Tani A, Kajiya Y, Shimaoka S, Matsuda A, Nioh T, Nihara T, Suenaga T, Tanaka S, Shirahama H, Higashi M, Koriyama C. Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas. Eur Radiol. 2011;21:2396-2407. [PMID: 21750887 DOI: 10.1007/s00330-011-2196-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
77 Yen TJ, Chung CS, Wu YW, Yen RF, Cheng MF, Lee JM, Hsu CH, Chang YL, Wang HP. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma. Dis Esophagus. 2012;25:40-47. [PMID: 21595776 DOI: 10.1111/j.1442-2050.2011.01204.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
78 Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/CT imaging in oncology. Ann Saudi Med 2011;31:3-13. [PMID: 21245592 DOI: 10.4103/0256-4947.75771] [Cited by in Crossref: 120] [Cited by in F6Publishing: 137] [Article Influence: 10.9] [Reference Citation Analysis]
79 Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: A review. Ann Surg Oncol. 2011;18:3338-3352. [PMID: 21537872 DOI: 10.1245/s10434-011-1732-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
80 Humbert O, Dygai-cochet I, Gauthier M, Cochet A, Berriolo-riedinger A, Crehange G, Toubeau M, Brunotte F. Valeur pronostique de la TEP au 18F-FDG dans le bilan d’extension initial du cancer de l’œsophage traité par radiochimiothérapie exclusive. Médecine Nucléaire 2011;35:186-94. [DOI: 10.1016/j.mednuc.2011.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Graff P, Schipman B, Desandes E, Mecellem H, Toussaint B, Cortese S, Marchal F, Kaminsky MC, Geoffrois L, Peiffert D. Management of patients with head and neck tumours presenting at diagnosis with a synchronous second cancer at another anatomic site. Clin Oncol (R Coll Radiol) 2011;23:174-81. [PMID: 21130631 DOI: 10.1016/j.clon.2010.10.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
82 Gyobu K, Yamashita S, Matsuda Y, Igaki H, Niwa T, Oka D, Kushima R, Osugi H, Lee S, Suehiro S, Ushijima T. Identification and Validation of DNA Methylation Markers to Predict Lymph Node Metastasis of Esophageal Squamous Cell Carcinomas. Ann Surg Oncol 2011;18:1185-94. [DOI: 10.1245/s10434-010-1393-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
83 Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV. Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. Eur Radiol 2011;21:274-80. [DOI: 10.1007/s00330-010-1943-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
84 van Heijl M, Omloo JM, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW, Boellaard R. Influence of ROI definition, partial volume correction and SUV normalization on SUV–survival correlation in oesophageal cancer. Nuclear Medicine Communications 2010;31:652-8. [DOI: 10.1097/mnm.0b013e3283390c56] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
85 Muijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT, Langendijk JA. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol. 2010;97:165-171. [PMID: 20541273 DOI: 10.1016/j.radonc.2010.04.024] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
86 Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, Murthy SC, Mason DP, Ives DI. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5:229-235. [PMID: 20009775 DOI: 10.1097/jto.0b013e3181c5e334] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
87 Oguma J, Ozawa S, Saikawa Y, Kitagawa Y. Surgical treatments for squamous cell carcinoma of the esophagus reaching to the muscularis mucosa or the upper third of the submucosal layer. Oncol Lett 2010;1:521-5. [PMID: 22966336 DOI: 10.3892/ol_00000092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
88 Roedl JB, Blake MA, Holalkere NS, Mueller PR, Colen RR, Harisinghani MG. Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters. Abdom Imaging. 2009;34:610-617. [PMID: 18830663 DOI: 10.1007/s00261-008-9447-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
89 Muijs CT, Schreurs LM, Busz DM, Beukema JC, van der Borden AJ, Pruim J, Van der Jagt EJ, Plukker JT, Langendijk JA. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol. 2009;93:447-453. [PMID: 19765847 DOI: 10.1016/j.radonc.2009.08.030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
90 Kim MK, Cho K, Park S, Kim YH, Kim JH, Song H, Shin JH, Jung HY, Lee GH, Choi KD, Song HJ, Ryu J, Kim S. Initial Stage Affects Survival Even After Complete Pathologic Remission is Achieved in Locally Advanced Esophageal Cancer: Analysis of 70 Patients With Pathologic Major Response After Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 2009;75:115-21. [DOI: 10.1016/j.ijrobp.2008.10.074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
91 Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, Fukuchi M, Oriuchi N, Endo K, Kuwano H. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196-3203. [PMID: 19472406 DOI: 10.1002/cncr.24399] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
92 Jadvar H, Henderson RW, Conti PS. 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol. 2006;8:193-200. [PMID: 16565910 DOI: 10.1007/s11307-006-0036-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
93 Gananadha S, Hazebroek EJ, Leibman S, Berry H, Osgood L, Shon IH, Pavlakis N, Marx G, Smith GS. The utility of FDG-PET in the preoperative staging of esophageal cancer. Dis Esophagus 2008;21:389-94. [PMID: 19125791 DOI: 10.1111/j.1442-2050.2007.00802.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
94 Salavati A, Basu S, Heidari P, Alavi A. Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nucl Med Commun 2009;30:95-116. [PMID: 19194210 DOI: 10.1097/MNM.0b013e32831af204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
95 Okada M, Murakami T, Kumano S, Kuwabara M, Shimono T, Hosono M, Shiozaki H. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med. 2009;23:73-80. [PMID: 19205841 DOI: 10.1007/s12149-008-0209-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
96 Williams RN, Ubhi SS, Sutton CD, Thomas AL, Entwisle JJ, Bowrey DJ. The early use of PET-CT alters the management of patients with esophageal cancer. J Gastrointest Surg. 2009;13:868-873. [PMID: 19184245 DOI: 10.1007/s11605-009-0812-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
97 Gemmel F, Roosjen H, van der Wijk P, Collins J. Subcutaneous metastasis from an occult esophageal cancer detected by PET-CT. Clin Nucl Med 2008;33:866-7. [PMID: 19033790 DOI: 10.1097/RLU.0b013e31818bf199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
98 Chowdhury F, Bradley K, Gleeson F. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma. Clinical Radiology 2008;63:1297-309. [DOI: 10.1016/j.crad.2008.05.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
99 Heron DE, Andrade RS, Beriwal S, Smith RP. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol 2008;31:352-62. [PMID: 18845994 DOI: 10.1097/COC.0b013e318162f150] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
100 Chatterton BE, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B, Wong D, Ramshaw JE, Scott AM. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: Results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:354-361. [PMID: 18931839 DOI: 10.1007/s00259-008-0959-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
101 Quint LE, Bogot NR. Staging esophageal cancer. Cancer Imaging. 2008;8 Spec No A:S33-S42. [PMID: 18852079 DOI: 10.1102/1470-7330.2008.9007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
102 Roedl JB, Colen RR, King K, Fischman AJ, Mueller PR, Blake MA. Visual PET/CT scoring for nonspecific 18F-FDG uptake in the differentiation of early malignant and benign esophageal lesions. AJR Am J Roentgenol 2008;191:515-21. [PMID: 18647925 DOI: 10.2214/AJR.07.3320] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
103 Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus 2008;21:241-50. [PMID: 18430106 DOI: 10.1111/j.1442-2050.2007.00766.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
104 Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:818-823. [PMID: 18718726 DOI: 10.1016/j.ijrobp.2008.04.062] [Cited by in Crossref: 58] [Cited by in F6Publishing: 67] [Article Influence: 4.1] [Reference Citation Analysis]
105 Touboul E, Huguet F, Talbot JN. [Use of PET for staging, treatment evaluation, and follow-up in esophageal cancers]. Cancer Radiother 2008;12:633-9. [PMID: 18693057 DOI: 10.1016/j.canrad.2008.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
106 Kim MK, Kim SB, Ahn JH, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song H, Shin JH, Cho K, Ryu J, Park S. Treatment Outcome and Recursive Partitioning Analysis-Based Prognostic Factors in Patients With Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 2008;71:725-34. [DOI: 10.1016/j.ijrobp.2007.10.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
107 Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, Han A, Song P, Li H, Yang G. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;73:136-141. [PMID: 18538492 DOI: 10.1016/j.ijrobp.2008.04.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
108 Miyata H, Doki Y, Yasuda T, Yamasaki M, Higuchi I, Makari Y, Matsuyama J, Hirao T, Takiguchi S, Fujiwara Y, Monden M. Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus. Dis Esophagus. 2008;21:144-150. [PMID: 18269650 DOI: 10.1111/j.1442-2050.2007.00743.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
109 Erasmus JJ, Rohren EM, Hustinx R. PET and PET/CT in the Diagnosis and Staging of Esophageal and Gastric Cancers. PET Clinics 2008;3:135-45. [DOI: 10.1016/j.cpet.2008.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
110 Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations on the Use of 18 F-FDG PET in Oncology. J Nucl Med 2008;49:480-508. [DOI: 10.2967/jnumed.107.047787] [Cited by in Crossref: 714] [Cited by in F6Publishing: 618] [Article Influence: 51.0] [Reference Citation Analysis]
111 Vinjamuri S, Ray S. Added value of PET and PET–CT in oesophageal cancer: a review of current practice. Nuclear Medicine Communications 2008;29:4-10. [DOI: 10.1097/mnm.0b013e3282f1b9c7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
112 van Westreenen HL, Westerterp M, Sloof GW, Groen H, Bossuyt PM, Jager PL, Comans EF, van Dullemen HM, Fockens P, Stoker J. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg. 2007;94:1515-1520. [PMID: 17902092 DOI: 10.1002/bjs.5708] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
113 van Vliet EP, van der Lugt A, Kuipers EJ, Tilanus HW, van der Gaast A, Hermans JJ, Siersema PD. Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol 2007;96:200-6. [PMID: 17455243 DOI: 10.1002/jso.20819] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
114 Collins CD. PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging 2007;7 Spec No A:S77-87. [PMID: 17921085 DOI: 10.1102/1470-7330.2007.9008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
115 Katsoulis IE, Wong WL, Mattheou AK, Damani N, Chambers J, Livingstone JI. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study. Int J Surg 2007;5:399-403. [PMID: 17631431 DOI: 10.1016/j.ijsu.2007.05.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
116 Pfau PR, Perlman SB, Stanko P, Frick TJ, Gopal DV, Said A, Zhang Z, Weigel T. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc. 2007;65:377-384. [PMID: 17321235 DOI: 10.1016/j.gie.2006.12.015] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
117 Westerterp M, Van Westreenen HL, Sloof GW, Plukker JT, Van Lanschot JJ. Role of positron emission tomography in the (re-)staging of oesophageal cancer. Scand J Gastroenterol Suppl 2006;:116-22. [PMID: 16782630 DOI: 10.1080/00365520600664409] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
118 Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360-385. [PMID: 17255408 DOI: 10.1148/radiol.2422051113] [Cited by in Crossref: 267] [Cited by in F6Publishing: 219] [Article Influence: 17.8] [Reference Citation Analysis]
119 Dam HQ, Manzone TM, Sagar VV. Evolving role of (18)F-fluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma. Surg Oncol Clin N Am 2006;15:733-49. [PMID: 17030270 DOI: 10.1016/j.soc.2006.07.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
120 Ott K, Weber W, Siewert J. The importance of Pet in the diagnosis and response evaluation of esophageal cancer. Diseases of the Esophagus 2006;19:433-42. [DOI: 10.1111/j.1442-2050.2006.00617.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
121 Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, Shimizu T, Shuto K, Hayashi H, Ochiai T. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg 2006;30:1441-9. [PMID: 16871357 DOI: 10.1007/s00268-005-0462-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 4.7] [Reference Citation Analysis]
122 Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, Rusch V. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg. 2006;81:1076-1081. [PMID: 16488726 DOI: 10.1016/j.athoracsur.2005.09.063] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
123 Rosenbaum SJ, Stergar H, Antoch G, Veit P, Bockisch A, Kühl H. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging. 2006;31:25-35. [PMID: 16333707 DOI: 10.1007/s00261-005-0031-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
124 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
125 Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Yokomakura N, Uenosono Y, Ishigami S, Owaki T, Aikou T. Individualization of lymphadenectomy in superficial esophageal squamous cell cancer. Esophagus 2006;3:41-5. [DOI: 10.1007/s10388-006-0070-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
126 Bombardieri E. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging 2006;33:753-8. [DOI: 10.1007/s00259-006-0147-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
127 Goyal L, Hingmire S, Parikh PM. Newer Diagnostic Methods in Oncology. Medical Journal Armed Forces India 2006;62:162-8. [DOI: 10.1016/s0377-1237(06)80062-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, Pitman A, Lau EW, MacManus M, Binns D. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol. 2006;78:254-261. [PMID: 16545881 DOI: 10.1016/j.radonc.2006.02.014] [Cited by in Crossref: 138] [Cited by in F6Publishing: 119] [Article Influence: 8.6] [Reference Citation Analysis]
129 Duong CP, Demitriou H, Weih L, Thompson A, Williams D, Thomas RJ, Hicks RJ. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:759-69. [PMID: 16470369 DOI: 10.1007/s00259-005-0028-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
130 Chin BB, Chang PP. Gastrointestinal malignancies evaluated with 18F-fluoro-2-deoxyglucose positron emission tomography. Best Practice & Research Clinical Gastroenterology 2006;20:3-21. [DOI: 10.1016/j.bpg.2005.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
131 Plukker J, van Westreenen H. Staging in oesophageal cancer. Best Practice & Research Clinical Gastroenterology 2006;20:877-91. [DOI: 10.1016/j.bpg.2006.05.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
132 Lee TJ, Lou HY, Lee CM, Hsu CH. Metastatic lymph node and osteolytic skeletal metastasis detected by FDG-PET in an endoscopy-diagnosed early-stage esophageal cancer. Clin Nucl Med 2005;30:760-2. [PMID: 16237309 DOI: 10.1097/01.rlu.0000182280.52207.96] [Reference Citation Analysis]
133 Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Kuwano H. Positron emission tomography in esophageal cancer. Esophagus 2005;2:111-21. [DOI: 10.1007/s10388-005-0053-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
134 Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med 2005;19:167-77. [PMID: 15981668 DOI: 10.1007/BF02984601] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
135 Gore RM. Upper gastrointestinal tract tumours: diagnosis and staging strategies. Cancer Imaging 2005;5:95-8. [PMID: 16154827 DOI: 10.1102/1470-7330.2005.0020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
136 Moureau-zabotto L, Touboul E, Lerouge D, Deniaud-alexandre E, Grahek D, Foulquier J, Petenief Y, Grès B, El Balaa H, Kerrou K, Montravers F, Keraudy K, Tiret E, Gendre J, Grange J, Hourry S, Talbot J. Tomographie par émission de positons et fusion d'images de simulation virtuelle par tomodensitométrie. Impact sur la planification de la radiothérapie conformationnelle des cancers de l'œsophage. Cancer/Radiothérapie 2005;9:152-60. [DOI: 10.1016/j.canrad.2005.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
137 Castillo E, Lawler LP. Diagnostic radiology and nuclear medicine. J Surg Oncol 2005;92:191-202. [DOI: 10.1002/jso.20360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]